The New Scientist report highlights a mouse study where cholesterol-depleting agent methyl β-cyclodextrin (meβCD) stiffened melanoma cells, boosting CAR-T efficacy. In the experiment, 24 mice received melanoma injections followed by engineered T-cells and IL-15; half also got daily meβCD tumor injections from days 9-18. After one month, all 12 untreated mice died while five of 12 meβCD-treated mice achieved complete tumor regression. This aligns with T-cell mechanosensing, where softer cancer membranes—rich in cholesterol—hinder stable immune synapses and perforin delivery. Yet the coverage underplays broader context: CAR-T remains largely ineffective against solid tumors due to physical barriers and immunosuppressive microenvironments, as shown in a 2022 Nature Reviews Cancer analysis of over 100 trials. The meβCD approach offers a physical rather than purely molecular fix, potentially complementing strategies like checkpoint inhibitors. Limitations include the small sample, lack of long-term survival data beyond 30 days, and direct intratumoral delivery that may not scale. No peer-reviewed publication exists yet; findings were presented at a 2024 biophysical conference. Related work from 2023 in Cell Reports on membrane mechanics confirms cholesterol modulation alters T-cell adhesion across species. If optimized for systemic use, this near-term tactic could extend CAR-T to pancreatic and breast cancers by exploiting conserved softness traits in human and murine tumors.